Literature DB >> 36068461

Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.

Zahra Talebi1, Alex Sparreboom2, Susan I Colace3,4.   

Abstract

Pharmacogenetic testing in patients with cancer requiring cytotoxic chemotherapy offers the potential to predict, prevent, and mitigate chemotherapy-related toxicities. While multiple drug-gene pairs have been identified and studied, few drug-gene pairs are currently used routinely in the clinical status. Here we review what is known, theorized, and unknown regarding the use of pharmacogenetic testing in cancer.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer; Chemotherapy; Efficacy; Pharmacogenetics; Pharmacogenomics; Toxicity

Mesh：

Year:  2022        PMID： 36068461     DOI： 10.1007/978-1-0716-2573-6_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  87 in total

1.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; J K Hicks; M Schwab; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2013-01-17       Impact factor: 6.875

3.  Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.

Authors:  Jun J Yang; Wendy Landier; Wenjian Yang; Chengcheng Liu; Lindsey Hageman; Cheng Cheng; Deqing Pei; Yanjun Chen; Kristine R Crews; Nancy Kornegay; F Lennie Wong; William E Evans; Ching-Hon Pui; Smita Bhatia; Mary V Relling
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

4.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Authors:  M V Relling; M L Hancock; G K Rivera; J T Sandlund; R C Ribeiro; E Y Krynetski; C H Pui; W E Evans
Journal:  J Natl Cancer Inst       Date:  1999-12-01       Impact factor: 13.506

5.  Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase.

Authors:  R Weinshilboum
Journal:  Drug Metab Dispos       Date:  2001-04       Impact factor: 3.922

6.  Thiopurine pathway.

Authors:  Gianluigi Zaza; Meyling Cheok; Natalia Krynetskaia; Caroline Thorn; Gabriele Stocco; Joan M Hebert; Howard McLeod; Richard M Weinshilboum; Mary V Relling; William E Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-09       Impact factor: 2.089

Review 7.  Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.

Authors:  Liming Weng; Li Zhang; Yan Peng; R Stephanie Huang
Journal:  Pharmacogenomics       Date:  2013-02       Impact factor: 2.533

Review 8.  Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children.

Authors:  Tiphaine Adam de Beaumais; Evelyne Jacqz-Aigrain
Journal:  Curr Drug Metab       Date:  2012-07       Impact factor: 3.731

Review 9.  Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy.

Authors:  Zeina N Al-Mahayri; George P Patrinos; Bassam R Ali
Journal:  Front Pharmacol       Date:  2020-04-15       Impact factor: 5.810

10.  Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.

Authors:  Gareth J Walker; James W Harrison; Graham A Heap; Michiel D Voskuil; Vibeke Andersen; Carl A Anderson; Ashwin N Ananthakrishnan; Jeffrey C Barrett; Laurent Beaugerie; Claire M Bewshea; Andy T Cole; Fraser R Cummings; Mark J Daly; Pierre Ellul; Richard N Fedorak; Eleonora A M Festen; Timothy H Florin; Daniel R Gaya; Jonas Halfvarson; Ailsa L Hart; Neel M Heerasing; Peter Hendy; Peter M Irving; Samuel E Jones; Jukka Koskela; James O Lindsay; John C Mansfield; Dermot McGovern; Miles Parkes; Richard C G Pollok; Subramaniam Ramakrishnan; David S Rampton; Manuel A Rivas; Richard K Russell; Michael Schultz; Shaji Sebastian; Philippe Seksik; Abhey Singh; Kenji So; Harry Sokol; Kavitha Subramaniam; Anthony Todd; Vito Annese; Rinse K Weersma; Ramnik Xavier; Rebecca Ward; Michael N Weedon; James R Goodhand; Nicholas A Kennedy; Tariq Ahmad
Journal:  JAMA       Date:  2019-02-26       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.